Early phase human clinical trials have shown that oncolytic herpes simplex virus (oHSV) vectors as a therapy for recurrent brain tumors are safe without treatment-related severe adverse events and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback